Acetylsalicylic acid is one of the most interesting drugs. Ever since it was synthesized in 1897 by Felix Hoffman, pharmacologically defined by Dreser and marketed in 1899 it has continued to challenge clinicians and researchers by demonstrating new scientific properties. In recent years, discussion has focused on its use as a prophylactic antithrombotic in venous and arterial vessel diseases. Stimulus in this direction originated from hemorrhagic diathesis after the intake of ASA as an analgesic or anti-rheumatic agent. In searching for causal relationships it was established that ASA has a dose-dependent influence on the platelets and coagulation system. Doses of less than 2 g have the following effects on the platelets:
(1) Inhibition of shape change.
(2) Inhibition of adhesiveness.
(3) Inhibition of ADP, epinepht ine, thrombin and collagen-induced aggregation and spontaneous aggregation.
(4) Inhibition of the availability of platelet factor 3 (PF3). (5) Inhibition of the release of ADP and platelet factor 4 (PF4).
Even after 50 mg of aspirin, collagen or epinephrine-induced aggregation is significantly reduced; 200 mg causes a complete inhibition of aggregation. In contrast, for the inhibition of coagulation factors PF 3 and PF 4 at least 500 mg is required. According to more recent studies the same dose-dependency is also valid for the influence of shape change. Coagulatory defects only occur after prolonged administration of doses of more than 3 g as used for the treatment of rheumatism. These effects are similar but milder than those induced by coumarin. An ASAinduced hypoprothrombinwmia can be recognized by a slight decrease in the activities of factors II, VII, IX and X. These changes can be corrected by administering vitamin K.
The recommendation of ASA as a therapeutic principle is based on new findings on thrombogenesis and on the interaction of ASA with the platelets. This was suggested by those investigators who found disturbances in platelet function sLIch as shape change, adhesion and aggregation in patients in the postoperative phase, after a trauma and recurrent venous thrombosis. Some authors demonstrated a causal connexion between increased aggregatability and subsequent angiological complications (Table 1) .
Further, the platelets take part in the introduction of coagulation induced by the release of the procoagulatory factors PF 3 and PF 4. When stasis-induced hypercoagulability in healthy volunteers was used as a model for venous thrombogenesis, it was observed that besides activation of plasmatic and fibrinolytic factors, an increase in platelet aggregation and a decrease in PF 4 plus an increase of activity in plasma was seen (Fig 1) . In the meantime, numerous prospec- tive studies have been published on postoperative thromboembolism with ASA alone or in combinawith dipyridamol. Many of the studies show that, in general surgery, ASA compared with placebo significantly reduces the risk of postoperative thromboembolism. Negative results were usually recorded after hip replacements or when doses of less than 1 g were administered.
As ASA only acts on a part of the heemostatic system, it is not possible to expect complete antithrombotic protection. As a result, combinations are recommended, e.g. together with low-dose heparin. Both substances have an additive effect and inhibit the activation of factor X in the early phase. To confirm this therapeutic schedule a clinical study was carried out on 177 patients. Group 1 received 1.5 g ASA i.v.; Group 2 received 5000 u heparin s.c.; and Group 3 received a combination of 1.5 g ASA-5000 u heparin s.c. Criteria for the presence of a thrombosis were:
(1) increased activity of more than 15%; (2) activity of more than 20% compared to the corresponding point; (3) persistence of the increased activity on the following days.
The fibrinogen test in the ASA group was positive in 30% of the cases; in the low-dose heparin group it was 19 % and in the combination group it was only 9 %. The combination therapy was significantly more effective than single drug treatment. Interestingly in the thigh there is no difference between ASA and low-dose heparin regarding 1 25-fibrinogen-activity. In contrast, in the calf more fibrinogen thromboses were observed after ASA than after low-dose heparin.
It has been generally accepted that adhesion and aggregation of platelets belong to the early changes in the morphogenesis of obliterative arteriopathies and that the platelets are involved in the construction of micro-thrombi in advanced stenosis or segmental obliteration of larger arteries. The particular importance of platelets in hemostasis is evident from the studies carried out by Marx and Kuhn. Using indirect immunofluorescence they determined collagen, type III, in arterial walls. This type of collagen has a considerably stronger aggregating activity than type I (skin collagen) and type II (cartilage collagen).
In experiments on mini-pigs, imitating the risk factors for obliterating arteriopathies in man, Hess et al. showed that platelet adhesion was present on the endothelium of different arteries after local irritation with ice and epinephrine as well as after systemic stimulation using cholesterol or the inhalation of cigarette smoke. The fate of these platelets differs quite considerably. They can scale off the wall or become incorporated in the endothelium without trace. It is, however, also possible that from the ulcerous plaques micro-aggregates continually embolize into the periphery and there cause transitory microcirculatory disturbances. Finally, an occlusive thrombus may develop due to the continued separation of platelets, fibrin and erythrocytes.
According to more recent biochemical results the prostaglandins are responsible for the adhesion of platelets to the vessel walls. The basis for this theory is the different ways ofmetabolizing arachidonic acid in platelets and in the vessel wall. It is assumed that in the platelets the cyclic endoperoxides PGG2 and PGH2 are metabolized to thromboxane A2, which enhances aggregation and has a vasoconstrictory effect. In contrast, in vessel walls a potent antagonist, prostacyclin,
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Amchkkoc acid (Fig 2) . In damaged vessel walls the synthesis of prostacyclin is disturbed and the thrombosispromoting antagonist, thromboxane A2, predominates.
To examine this therapeutic principle based on pathophysiology and experimental results a series of long-term clinical studies was carried out on different angiological diseases. Indications were peripheral arteriopathy, prophylactic therapy after vascular surgery, prevention of thromboembolic -'omplication in patients with artificial ball valves, prophylaxis of transitoiy attacks and prophylaxis of re-infarction ( Table 2 ).
The prevention of re-occlusion of reconstructed peripheral vascular segments is still a problem which has not been completely solved. The most important causes are mechanical-htmodynamic factors, the particular tendency to thrombosis at roughened intima surfaces, the continued presence of risk factors and the progression of the basic disease. The basic requirement is the surgical reconstruction of the vessel. Much contested and still not fully defined is the use of anticoagulants as they cannot prevent re-occlusion caused by indication errors or technical problems. On the other hand, during the first few postoperative weeks, there is a great tendency to thrombosis in the vessel and anti-thrombotic therapy is necessary. In a double-blind study 428 patients were treated after vascular surgery either with microencapsulated ASA or placebo for one year. At intervals of three months the patients were subjected to clinical follow ups which included oscillographic tests and when a re-occiusion was suspected an angiogram was taken. Where the varying degree of severity of the occlusion was the deciding factor to operate, stage Ilb was responsible in 74W% of the cases, stage III in 14-17% and stage IV in 10-12%. With few exceptions we were concerned with a chronic arterial occlusion, i.e. in more than 6004 of the cases the time-lapse between onset of disease and surgical intervention was more than one year. The preferred reconstruction procedure was endarteriectomy. Of 428 patients 307 were treated for one year. On reviewing the uncomplicated cases it became evident that the surgical intervention resulted in an improvement of the Fontaine stage from, on average, 2.5 for both therapeutic groups to 1.1. This result does not alter within the two treatment groups during the first twelve months. During a one-year observation period re-occlusions were observed in 71 (17%) of the 428 patients. In the ASA group a total of 24 (11 .2 %) were observed and in the placebo group 47 (22 %). The statistical analysis revealed that 1.5 g ASA daily significantly reduced the incidence of re-occlusions when compared with placebo. of the study was to establish whether ASA or phenprocoumon compared with placebo is able to prevent a re-infarction or death due to myocardial infarction.
The organization scheme of the study included the coordinator, the statistician, the clinical centres and advisory board (Fig 3) . The patients were randomly allocated in the individual therapy groups within strata (hospitals, age, sex, reinfarction, hyperlipidaemia). Randomization shows no differences exist between the individual groups regaiding social class, age and sex as well as for the main risk factors such as overweight, hypertension, diabetes mellitus, hyperuricwmia, smokers, evaluation and localization of infarction.
The overall results show that 56 % of the patients passed the study period without interruption; 12.2% had to be excluded for technical reasons; 10.5% were lost to follow up; 1.2% had intercurrent diseases; 6.3 % dropped out because of side effects of drugs and 3.9 % died as a result of other diseases. The aim of the study was to analyse the incidence of survived re-infarctions or death due to re-infarction. Compared with placebo or phenprocoumon, markedly fewer myocardial infarction and sudden deaths occurred under ASA. In contrast, under phenprocoumon the incidence of survived re-infarctions was smaller than in the placebo group. At present the study is being statistically assessed. The preliminary analysis, however, allows the following conclusions to be drawn:
(1) During a two-year observation period more patients in the placebo and phenprocoumon groups died as a result of secondary myocardial infarction or sudden death than in the ASA group.
(2) Under phenprocoumon fewer patients with survived re-infarction were observed than under placebo.
(3) Under ASA treatment fewer secondary myocardial infarctions and sudden deaths were observed than under placebo or phenprocoumon.
(4) HWemorrhagic complications were equally frequent under ASA and phenprocoumon; stomach complaints were more frequently observed in the ASA group.
Conclusions
On the basis of more recent pathophysiological knowledge the platelets, because of their morphological and dynamic behaviour are involved in the formation of venous and arterial thromboses. Details of the mechanisms which cause scaling off of platelets from the vessel wall are still not fully explained. However, three important causes are:
(1) Morphological changes of the vessel wall such as arteriosclerotic plaques and exposed collagen.
(2) Biochemical disturbances between vessel wall and circulating blood. How far the prostaglandin system is involved has still to be defined in further experimental and biological studies.
(3) External trigger mechanisms due to external risk factors, e.g. smoking, and accompanying illnesses such as diabetes mellitus, fat metabolic disturbances and hypertension.
Since ASA influences the vessel wall and the platelets it appeared sensible to test this therapeutic principle clinically. Over the last seven years we have compared ASA with placebo or anticoagulants on different venous and arterial models such as the prophylaxis of thromboembolism, prophylaxis of peripheral vascular, cardiovascular and cerebrovascular diseases in prospective randomized studies. The results obtained to date justify the prophylactic use of ASA in venous and arterial diseases. As an antithrombotic agent against venous thromboembolism it is necessary that a combination, either with another aggregation inhibitor, or preferably with low-dose heparin, should be striven for. ASA alone is too weak when compared with present-day venous antithrombotic principles. In arteriopathies ASA should be considered a basic therapy. However, a prerequisite is a sufficiently high dose.
